Semax Chemical

The literature

Semax References

Every study cited across this digest, listed with its identifiers.

About these sources

Every quantitative claim on this site maps to a numbered study below. The list is dominated by Russian research groups, reflecting where the Semax literature actually lives, and ranges from binding and enzyme assays through genome- and proteome-wide ischemia studies to the few human EEG and clinical reports. Links go to PubMed or PubMed Central; digital object identifiers (DOIs) are given where available.

  1. Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-6. ↗
  2. Agapova TY, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neurosci Lett. 2007;417(2):201-5. ↗
  3. Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim (Russ J Bioorg Chem). 2001;27(3):180-183. ↗
  4. Romanova GA, et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bull Exp Biol Med. 2006;142(6):663-6. ↗
  5. Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. ↗
  6. Shevchenko KV, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russ J Bioorg Chem (Bioorg Khim). 2006;32(1):57-62. ↗
  7. Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. ↗
  8. Stavchansky VV, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. ↗
  9. Filippenkov IB, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681. ↗
  10. Filippenkov IB, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. Int J Mol Sci. 2021;22(12):6179. ↗
  11. Filippenkov IB, et al. The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain. Dokl Biochem Biophys. 2021;498(1):152-156. ↗
  12. Filippenkov IB, et al. Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period. Genes (Basel). 2023;14(7):1382. ↗
  13. Agapova TY, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. ↗
  14. Bashkatova V, et al. Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Res. 2001;894(1):145-149. ↗
  15. Volodina MA, et al. Correction of Long-Lasting Negative Effects of Neonatal Isolation in White Rats Using Semax. Acta Naturae. 2012;4(1):86-92. ↗
  16. Shevchenko KV, et al. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci. 2013;449:98-100. ↗
  17. Effect of the heptapeptide Semax on the human electroencephalogram. Biull Eksp Biol Med. 1996;121(1):26-30. ↗
  18. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):54-57. ↗
  19. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):11-14. ↗
  20. Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. ↗